AI Science Tracker

Kimia Therapeutics

1 discovery from 2026

Discoveries

D2ML guided prospective ROS1 potency and selectivity optimization

Assay-aware models were used to select 84 new compounds for synthesis and prospective testing in a ROS1 kinase program, with TRKB as an anti-target. The most selective prospective compound had a measured ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB, compared with 20.3 nM and 79-fold for the most selective training-set compound. The evidence is biochemical and does not establish therapeutic efficacy or safety.

Technology: D2ML multi-stage deep neural networks trained across direct-to-biology assay data

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: The authors prospectively synthesized and assayed 84 model-selected compounds. The most selective new compound had ROS1 IC50 14.7 nM and 233-fold selectivity over TRKB; the most selective training compound had 20.3 nM ROS1 IC50 and 79-fold selectivity.
  • Still unknown: This is an in-vitro biochemical discovery result. It does not establish cellular activity, therapeutic efficacy, safety or clinical benefit. The paper compares a historical analog but makes no claim of global chemical novelty.
  • AI role: Assay-aware models using data from multiple direct-to-biology screening stages selected compounds for prospective synthesis and ROS1/TRKB testing.

Evidence sources: https://arxiv.org/abs/2610.41070 · https://arxiv.org/html/2610.41070v1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary arXiv v1 abstract, submission history and full text for date, affiliation, model methods and prospective assay result..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.